Does Pegasys Cause Hair Thinning or Loss?
Yes, hair thinning or loss (alopecia) is a reported side effect of Pegasys (peginterferon alfa-2a), an antiviral drug used for hepatitis B and C. Clinical trials and post-marketing data show it occurs in 10-25% of patients, often as diffuse thinning rather than complete baldness. It's linked to interferon-based therapies disrupting hair follicle cycles.[1][2]
How Common Is It and When Does It Start?
In phase 3 trials for chronic hepatitis C, alopecia affected up to 24% of patients on Pegasys plus ribavirin, compared to 1-5% on ribavirin alone. It typically begins 2-3 months into treatment, peaks around month 6, and may persist during the full 24-48 week course. Most cases are mild to moderate.[1][3]
Why Does Pegasys Trigger This?
Interferons like Pegasys induce telogen effluvium, shifting hair follicles prematurely from growth (anagen) to resting (telogen) phases. This stems from the drug's immune-modulating effects, causing inflammation around follicles. Ribavirin co-use can worsen it.[2][4]
Does It Grow Back After Stopping?
Hair usually regrows 3-6 months post-treatment as follicles recover, though full density may take up to a year. Persistent loss is rare unless underlying conditions like thyroid issues (also inducible by Pegasys) contribute.[1][5]
What Do Patients Report Online?
Forums like Drugs.com and HepC support groups note thinning as "very common," with some describing scalp itchiness or patchy loss. Women report it more noticeably. Many use minoxidil or biotin preemptively, though evidence for prevention is weak.[6]
How to Manage or Prevent It
No proven prevention exists, but options include:
- Topical minoxidil (5%) applied daily, starting early.
- Shampoos with ketoconazole for scalp health.
- Dose adjustments if severe, though rarely needed.
Consult a doctor before supplements, as they may interact.[2][5]
Compared to Other Hepatitis Treatments
Newer direct-acting antivirals (e.g., sofosbuvir-based regimens like Harvoni) have near-zero alopecia reports, making them preferable for hair-conscious patients. Pegasys is now rarely first-line.[3][7]
[1]: Pegasys Prescribing Information (FDA)
[2]: MedlinePlus - Peginterferon Alfa-2a
[3]: Hepatitis C Online - Side Effects
[4]: Journal of Clinical Virology - Alopecia in IFN Therapy (2008)
[5]: American Academy of Dermatology - Drug-Induced Hair Loss
[6]: Drugs.com - Pegasys Reviews
[7]: NEJM - DAA vs IFN Outcomes (2014)